Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 12/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23824133 | 0.98 | SMN1; SMN2 (0.49) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL29299819 | 0.95 | FOLH1 (0.51) | SMN1; SMN2TP53FOLH1ALB | |
| SCHEMBL13028392 | 0.95 | SMN1; SMN2 (0.43) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL24590552 | 0.94 | SMN1; SMN2 (0.50) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL29299673 | 0.93 | FOLH1 (0.45) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL20104885 | 0.92 | FOLH1 (0.43) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL29299828 | 0.92 | FOLH1 (0.48) | SMN1; SMN2TP53FOLH1ALDH1A1ALB | |
| SCHEMBL29299679 | 0.91 | ALDH1A1 (0.45) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL29299829 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2TP53FOLH1ALDH1A1SIGMAR1 | |
| SCHEMBL29299797 | 0.88 | DPP7 (0.46) | SMN1; SMN2TP53FOLH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459565-B1 | SAXITOXIN DERIVATIVES, METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | UNIV LELAND STANFORD JUNIOR (US) | 2018-05-02 | — | — | EP | disclosed |
| US-20160115173-A1 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2016-04-28 | — | — | US | disclosed |
| US-9174999-B2 | Methods and compositions for studying, imaging, and treating pain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-11-03 | — | — | US | disclosed |
| WO-2010129864-A9 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-03-08 | — | — | WO | disclosed |
| US-20100284913-A1 | Methods and compositions for studying, imaging, and treating pain | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIO (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2010129864-A2 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115173-A1 | METHODS AND COMPOSITIONS FOR STUDYING, IMAGING, AND TREATING PAIN | INA, SCN3A, SCN9A | SMN1; SMN2 45/4885TP53 4286/4885FOLH1 2566/4885 |
| US-20100284913-A1 | Methods and compositions for studying, imaging, and treating pain | INA, SCN3A, SCN9A | SMN1; SMN2 45/4885TP53 4286/4885FOLH1 2566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.